This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06628362 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 2 |
| Sponsor | Carmot Therapeutics, Inc. |
| Enrollment | 447 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Overweight or Obese; Type 2 Diabetes Mellitus (T2DM) |
| Interventions | Placebo; Enicepatide |
| Start | Nov 21, 2024 |
| Primary completion | May 29, 2026 |
| Study completion | Sep 24, 2026 |
| Results posted | Not yet |
| Registry last updated | Jun 24, 2026 |
| Collaborators | Hoffmann-La Roche |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change in Body Weight from Baseline to Week 36 | Baseline to Week 36 |
| Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36 | Baseline to Week 36 |
24 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
